Introduction
============

Epidemiological and toxicological research has identified adverse human health effects due to particulate air pollution exposure. Particulate matter ≤10 μm in aerodynamic diameter (PM~10~) is associated with increased hospital admissions and mortality due to pulmonary and cardiovascular diseases.[@b1-copd-10-831] Air pollutants participate in the development of pulmonary disease by interfering with both nonspecific and specific lung defenses.[@b2-copd-10-831] Chronic obstructive pulmonary disease (COPD), for instance, is recognized as an environmentally related pulmonary disease that is associated with exposure to air pollution.[@b3-copd-10-831] Schikowski et al[@b4-copd-10-831] in 2014, provided evidence that the chronic effects of air pollution affect the prevalence and incidence of COPD among adults. Kumar et al[@b5-copd-10-831] (2013) noted the association between acute COPD exacerbation and particulate air pollution, finding that the risk of acute COPD exacerbation increased by 2.3% following a unit increase in PM~2.5~ (≤2.5 μm). However, the effects of PM~10~ on protein expression in COPD are not well understood.

A protein biomarker is capable of objectively and quantitatively acting as an indicator to identify normal or pathological processes and the corresponding exposure to environmental stresses.[@b6-copd-10-831] For example, 8-isoprostane and C-reactive protein (CRP), the biomarkers for oxidative stress and inflammation, respectively, have been widely used to evaluate the cardiopulmonary toxicity of PM~10~.[@b7-copd-10-831],[@b8-copd-10-831] However, they are nonspecific PM~10~ biomarkers for oxidative inflammatory reactions. Thus, an increasing number of studies have attempted to identify more specific biomarkers for the assessment of specific pollutant exposures. For example, urinary p-nitrophenol has been reported to be a specific biomarker for occupational exposure to methyl parathion,[@b9-copd-10-831] and DNA modifications, such as *F2RL3* methylation, have been suggested as biomarkers for tobacco exposure.[@b10-copd-10-831] Ideally, a quality biomarker can be used for treatment and intervention decisions. However, biomarker measurement may also vary according to exposure sources and susceptible populations.

A useful biomarker not only differentiates stable disease from exacerbations but also predicts the severity of pollutant exposure. The objective of this study was to identify biomarkers for PM~10~ exposure in patients with COPD. This study identified and assessed the use of serum biomarkers in the evaluation of PM~10~ compared with the existing biomarkers of inflammation, namely 8-isoprostane and CRP. We used a proteomics approach to comprehensively screen protein profiles in healthy subjects and patients with COPD exposed to low and high levels of PM~10~ over the past 3 years. The identified protein candidates were determined in serum samples obtained from 50 patients with COPD and 15 subjects without COPD. The specific and sensitive values of 8-isoprostane, CRP, and identified biomarkers were compared.

Materials and methods
=====================

Study population
----------------

We recruited 50 patients with COPD and 15 subjects without COPD (nonsmokers and smokers) in a medical center in Taiwan between January 2013 and August 2014. All subjects were between 40 years and 80 years of age at the time of inclusion. Patients identified with current cancer or active inflammatory disease or who had an exacerbation during the 4 weeks before the study were excluded. All subjects with COPD were informed of diagnosis and exhibited postbronchodilation forced expiratory volume in 1 second (FEV~1~)/forced vital capacity (FVC) ratios of \<70%. Subjects without COPD exhibited an FEV~1~/FVC ratio of ≥75% and FEV~1~ ≥80% of predicted value. The Ethics Committees of Taipei Medical University-Joint Institutional Review Board approved the study protocol (number 201310027). The Chinese Clinical Trial Register number is ChiCTR-OCC-13004025. All subjects received written and oral information before inclusion and provided informed consent.

Data collection
---------------

Before recruitment into the study, a physical examination was performed, as was a clinical interview regarding smoking habits, comorbidities, and medicinal use. All subjects with COPD continued with a stable regimen of medications throughout the study. Lung function parameters were assessed at the time of recruitment using a Vitalograph Spirotac V™. Postbronchodilation measurements for FEV~1~ and FVC were taken, and FEV~1~/FVC was calculated. Serum samples were obtained and stored at −80°C for analysis.

PM~10~ exposure
---------------

PM~10~ data were obtained from 25 monitoring stations (operated by the Taiwan Environmental Protection Administration, Taiwan) throughout northern Taiwan. The daily concentrations of PM~10~ were collected, corresponding to subject exposure. If a subject resided within 10 km of multiple monitoring stations, the weighted average was used to calculate the PM~10~ levels. The PM~10~ data were used to estimate the 1-year, 2-year, and 3-year effects of PM~10~ on COPD.

Protein digestion
-----------------

To determine the effects of PM~10~ on protein expression in COPD, the five subjects with the highest average 3-year PM~10~ values were classified as the High Ambient Particles (HAP) group (exposure range =63.2--64.5 μg/m^3^), and the five subjects with the lowest average 3-year PM~10~ served as the Low Ambient Particles (LAP) group (exposure range =35.4--43.9 μg/m^3^). Serum samples from healthy controls, HAP, and LAP were collected and pooled together following protein digestion.[@b11-copd-10-831] After protein depletion to remove albumin and immunoglobulin, the serum samples were diluted and denatured with 8 M urea/10 mM ammonium bicarbonate for 1 hour; they were then alkylated with 50 mM iodoacetamide for 30 minutes, tryptically digested in a solution of 50 mM ammonium bicarbonate at 37°C for 18 hours, and desalted on C18 columns.

Mass spectrometry and protein identification
--------------------------------------------

Tryptic samples were analyzed using a mass spectrometer (LTQ Orbitrap XL; Thermo Fisher Scientific, Bremen, Germany) coupled with an Ultimate 3000 RSLC system (Dionex, Sunnyvale, CA, USA) using previously documented protocols.[@b12-copd-10-831] Briefly, peptides were separated using a 150 mm length ×100 mm inner diameter self-pulled spray tip (5 μm tip opening) and packed with C18 material (ReproSil; 3 μm; Dr Maisch, Ammerbuch, Germany). The linear gradient was from 5% to 10% of mobile phase B (mobile phase A: 0.5% acetic acid, mobile phase B: 80% acetonitrile/0.5% acetic acid) for 5 minutes, 10% to 40% of mobile phase B for 30 minutes, and 40% to 99% of mobile phase B for 5 minutes, with a total of 75 minutes' separation time. Five ranges of full mass spectrometry (MS) scans (*m/z* 350--2,000, *m/z* 350--600, *m/z* 600--800, *m/z* 800--1,200, and *m/z* 1,200--2,000) were followed by the selection of the ten most intense ions for MS/MS scans. Data were analyzed using the Proteome Discoverer 1.4 program to perform a Mascot database search of the National Center for Biotechnology Information and UniProt databases both for prediction as well as a literature search. The maximum mass tolerance was set to 10 ppm for precursor ions and 0.05 Da for fragment ions. Variable modifications for deamidation (NQ), oxidation (M), and fixed modification for carbamidomethyl (C) were selected for the search parameters.

Protein functional analyses
---------------------------

Unique proteins expressed in the HAP and LAP groups were analyzed using the Protein ANalysis THrough Evolutionary Relationships (PANTHER) classification system.[@b13-copd-10-831],[@b14-copd-10-831] The UniProt accession database was used to relate the expressed proteins identified in this study to related biological processes and molecular functions.

Enzyme-linked immunosorbent assay
---------------------------------

Enzyme-linked immunosorbent assays (ELISAs) were used to determine the serum levels of 8-isoprostane (Cayman, Ann Arbor, MI, USA), CRP (CRP; R D Systems, Minneapolis, MN, USA), proteoglycan 4 (PRG4), inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4), and apolipoprotein F (APOF; MyBioSource, San Diego, CA, USA) according to the manufacturer's instructions.

Statistical analysis
--------------------

All ELISA experiments were performed at least three times. Data are expressed as the mean ± standard deviation. For multiple comparison analysis, one-way analysis of variance with Tukey's post hoc was used. Spearman's rank correlation coefficient was used to examine the correlation of quintiles of PM~10~ with PRG4, ITIH4, and APOF, as well as the correlation of 8-isoprostane and CRP with PRG4, ITIH4, and APOF. Receiver operating characteristic (ROC) curve analysis was used to determine the specificity and sensitivity of PRG4, ITIH4, and APOF to PM~10~ (≥50 μg/m^3^ and \<50 μg/m^3^) in COPD. Statistical analyses were performed using GraphPad Version 5 (La Jolla, CA, USA) for Windows. The level of significance was set to *P*\<0.05.

Results
=======

Characteristics of study subjects
---------------------------------

Fifty subjects with COPD, ten healthy controls, and five healthy smoking volunteers were enrolled. Detailed baseline characteristics of the 65 subjects in the study population are presented in [Table 1](#t1-copd-10-831){ref-type="table"}. The ages of healthy controls, healthy smokers, and subjects with COPD were 67.8±6.2 years, 59.8±14.6 years, and 70.7±8.4 years, respectively. The majority of the study population consisted of men with body mass indexes that ranged between 22.5 kg/m^2^ and 24.8 kg/m^2^. The current smoking percentage among the subjects with COPD was 9.1%. The FEV~1~ percentages of predicted values for the healthy controls, healthy smokers, and subjects with COPD were 88.0%±11.5%, 85.5%±14.9%, and 42.6%±12.4%, respectively. The levels of 8-isoprostane and CRP for subjects with COPD were 13.4±3.0 pg/mL and 5.6±6.4 mg/L, respectively. The average PM~10~ concentrations for the study subjects were estimated, as shown in [Table 2](#t2-copd-10-831){ref-type="table"}, and were 46.0±8.4 μg/m^3^ for the 1-year average, 48.5±7.2 μg/m^3^ for the 2-year average, and 50.8±7.0 μg/m^3^ for the 3-year average.

Selection of potential biomarkers in patients with COPD
-------------------------------------------------------

Overlaps in protein profiles between healthy controls and the LAP- and HAP-exposed subjects with COPD were compared to investigate protein expression in COPD ([Figure 1A](#f1-copd-10-831){ref-type="fig"}). A total of 179 proteins were identified in the healthy controls, and 178 and 187 proteins were identified in the LAP- and HAP-exposed subjects with COPD, respectively (Table S1). A total of 14 and 23 proteins were unique to LAP- and HAP-exposed subjects with COPD, respectively. Six serum proteins were common to both LAP- and HAP-exposed subjects with COPD: PRG4, ITIH4, APOF, Ig kappa chain V-I region DEE, type I cytoskeletal 16 keratin, and type II cytoskeletal 6A keratin.

PANTHER analysis was conducted on the proteins unique to LAP- and HAP-exposed subjects with COPD to understand their biological context ([Figure 1B](#f1-copd-10-831){ref-type="fig"}). The common biological processes identified in the LAP and HAP groups included biological regulation (29% for LAP), cellular component organization or biogenesis (13% for HAP), cellular process (14% for LAP and 13% for HAP), developmental process (13% for HAP), immune system process (29% for LAP and 25% for HAP), localization (14% for LAP and 13% for HAP), metabolic process (14% for LAP and 13% for HAP), and response to stimulus (13% for HAP), with immune system process terms being the most common. The common molecular functions identified between the LAP and HAP groups included binding (50% for LAP and 50% for HAP), catalytic activity (17% for LAP and 25% for HAP), enzyme regulator activity (17% for LAP), structural molecule activity (25% for HAP), and transporter activity (17% for LAP), with binding terms being the most common.

Validation of PRG4, ITIH4, and APOF in patients with COPD and control subjects
------------------------------------------------------------------------------

The levels of PRG4, ITIH4, and APOF in healthy controls, smokers, and subjects with COPD are presented in [Figure 2](#f2-copd-10-831){ref-type="fig"}. There were no differences in the PRG4, ITIH4, and APOF levels between healthy controls and healthy smokers. The PRG4 levels in the subjects with COPD were significantly higher than those in healthy controls or smokers (*P*\<0.05). The ITIH4 levels in subjects with COPD were lower than those in healthy controls (*P*\<0.05) but not those of healthy smokers. There was no significant difference in the APOF levels across subjects with COPD, healthy controls, or smokers.

Correlation of PM~10~ with PRG4, ITIH4, and APOF
------------------------------------------------

The changes in PM~10~ for the 1-year, 2-year, and 3-year averages in quintiles were related to PRG4, ITIH4, and APOF ([Figure 3](#f3-copd-10-831){ref-type="fig"}). The PRG4 levels were correlated with 2-year (*r*=0.278, *P*=0.033) and 3-year (*r*=0.349, *P*=0.007) PM~10~ averages, whereas the ITIH4 levels were correlated with the 1-year (*r*=−0.325, *P*=0.012), 2-year (*r*=−0.401, *P*=0.002), and 3-year PM~10~ averages (*r*=−0.342, *P*=0.008). There was no correlation between APOF and PM~10~ levels over the previous 3 years.

[Figure 4](#f4-copd-10-831){ref-type="fig"} shows the ROC curve of the sensitivity and specificity obtained for the PRG4, ITIH4, and APOF levels when discriminating between the ≥50 μg/m^3^ and \<50 μg/m^3^ average 3-year PM~10~ levels in patients with COPD. The area under the curve (AUC) value was 0.563 (95% confidence interval \[CI\] =0.413--0.713, *P*=0.405) for 8-isoprostane, 0.634 (95% CI =0.486--0.782, *P*=0.086) for CRP, 0.636 (95% CI =0.492--0.780, *P*=0.083) for PRG4, 0.690 (95% CI =0.545--0.836, *P*=0.015) for ITIH4, and 0.523 (95% CI =0.376--0.671, *P*=0.766) for APOF.

Correlation of 8-isoprostane and CRP with PRG4, ITIH4, and APOF
---------------------------------------------------------------

Correlations between 8-isoprostane and CRP with PRG4, ITIH4, and APOF for COPD were determined ([Figure 5](#f5-copd-10-831){ref-type="fig"}). There were no statistical associations of 8-isoprostane and CRP to PRG4 and APOF in patients with COPD. Only ITIH4 was correlated with the CRP levels (*r*=0.353, *P*=0.005).

Discussion
==========

COPD, a chronic inflammatory disease, is recognized by irreversible airflow obstruction and by structural modifications in the proximal and peripheral airways.[@b15-copd-10-831] An abnormal inflammatory response of the lung to PM~10~ appears to play a central role in the pathogenesis of COPD;[@b16-copd-10-831],[@b17-copd-10-831] however, few studies have investigated protein profiles in patients with COPD residing in polluted urban areas. The present study discovered differences in protein expression in patients with COPD who were exposed to low and high levels of PM~10~ (LAP and HAP). Three major findings are reported in the present study: 1) immune system process and binding are the most important biological process and molecular function, respectively, in the response to PM~10~ in patients with COPD, 2) ITIH4 is a biomarker for PM~10~ in COPD, and 3) ITIH4 is associated with inflammatory response.

Oxidative stress and inflammatory reactions are considered common biological responses that result from the inhalation of PM~10~. Toxicology exposure experiments in animals and humans have identified several biological mechanisms that may be affected by the inhalation of PM~10~, including oxidative stress and systemic inflammation.[@b18-copd-10-831] The present study identified the immune system process as an important biological process in the response to PM~10~ in COPD and the binding terms as important molecular functions. Immune response is considered an important determinant for the exacerbation of COPD,[@b19-copd-10-831],[@b20-copd-10-831] and immune disorder commonly associated with PM~10~ contributes to lung function impairment and mortality. Systemic inflammation is considered a common link between COPD and immune response.[@b21-copd-10-831] Furthermore, a link between binding and COPD has been reported.[@b22-copd-10-831] For example, a heavy subunit with a regulatory light subunit can modulate glutamate cysteine ligase activity.[@b23-copd-10-831] Notably, a key common feature between PM~10~ exposure and COPD is "inflammatory response." Oxidative inflammatory reactions may be a result of exposure-related variances in protein regulation; therefore, an investigation of the effect of PM~10~ on protein profiling in COPD is important.

Discovering biomarkers for susceptible populations assists with human environmental exposure assessment and risk evaluation. Despite increased efforts to identify COPD biomarkers, however, the gap between clinical and environmental medicine is substantial. We identified six biomarker candidates from healthy controls and from LAP-and HAP-exposed patients with COPD using a proteomics approach on serum samples: PRG4, ITIH4, APOF, Ig kappa chain V-I region DEE, type I cytoskeletal 16 keratin, and type II cytoskeletal 6A keratin. Type I cytoskeletal 16 keratin and type II cytoskeletal 6A keratin are associated with epithelial tissues from nail beds, esophagus, tongue, and hair follicles,[@b24-copd-10-831],[@b25-copd-10-831] which are less likely related to the mechanisms of PM~10~ and COPD. Thus, we next examined PRG4, ITIH4, and APOF as candidate biomarkers. We observed that the PRG4 levels in subjects with COPD were significantly higher than those in healthy controls and smokers, whereas the ITIH4 levels were significantly lower than those in healthy controls. These results suggest PRG4 and ITIH4 could be the potential biomarkers for COPD and that APOF is not sensitive as a potential biomarker for COPD and PM~10~ exposure. We then correlated the PM~10~ levels for the previous 1-year, 2-year, and 3-year averages with these three biomarker candidates. The correlations showed that PRG4 and ITIH4 may be biomarkers for alteration in PM~10~ levels, particularly ITIH4. Previously, 8-isoprostane and CRP were characterized as biomarkers of oxidative stress and inflammation, respectively, in response to particulate air pollution.[@b7-copd-10-831],[@b26-copd-10-831] Therefore, we used them for the comparison with PRG4, ITIH4, and APOF in COPD. The US Environmental Protection Agency's health-based national air quality standard for PM~10~ (annual average of 50 μg/m^3^) was used as the cutoff level for the ROC analysis. We discovered that ITIH4 is the only significant biomarker for PM~10~ in COPD; no significance was observed for 8-isoprostane, CRP, PRG4, and APOF. This finding suggests that ITIH4 is a good biomarker for evaluating PM~10~ exposure in subjects with COPD.

To understand the potential mechanisms underlying PM~10~-regulated COPD in the present study, 8-isoprostane and CRP were correlated with PRG4, ITIH4, and APOF. Statistical significance was observed between CRP and ITIH4 in COPD, suggesting that ITIH4 may be involved in inflammatory responses. ITIH4 is a type II acute phase protein and has been associated with inflammatory responses.[@b27-copd-10-831],[@b28-copd-10-831] Our findings are consistent with those of a previous study that observed correlation between the ITIH4 and CRP levels.[@b27-copd-10-831],[@b28-copd-10-831] However, the correlations between PM~10~ and ITIH4 are negatively associated with increasing PM~10~ concentrations. CRP is commonly used in the assessment of several acute clinical conditions, such as COPD.[@b29-copd-10-831] Notably, CRP levels are also elevated in many other conditions, including infective, inflammatory, and neoplastic pathologies.[@b30-copd-10-831]--[@b32-copd-10-831] Because of CRP's involvement in multiple pathologies, ITIH4 may be a more specific biomarker for PM~10~ in COPD than CRP.

Conclusion
==========

In conclusion, circulating ITIH4 is an important biomarker to assess PM~10~ exposure in patients with COPD and could be involved in postexposure inflammatory responses. Furthermore, metabolic process and catalytic activity are the important biological process and molecular function, respectively, in response to PM~10~ exposure in COPD. The limitation of the present study is the sex distribution in the study subjects. The sex difference may associated with the biomarker identification for PM~10~ exposure. Future studies are required to investigate the potential mechanisms underlying PM~10~ exposure and to determine whether ITIH4 can provide a specific index for evaluating PM~10~ exposure in COPD.
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![Protein expression and biological process and molecular functions determined by PANTHER.\
**Notes:** (**A**) Venn diagram of proteins that are common among or unique to patients with COPD exposed to low ambient particles (LAP; range: 35.4--43.9 μg/m^3^) and high ambient particles (HAP; range: 63.2--64.5 μg/m^3^) compared with healthy controls exposed to either LAP or HAP. Six proteins were commonly expressed in the serum samples: proteoglycan 4 (PRG4), inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4), apolipoprotein F (APOF), Ig kappa chain V-I region DEE, type I cytoskeletal 16 keratin, and type II cytoskeletal 6A keratin. (**B**) The biological processes and molecular functions of the unique proteins identified in the LAP and HAP groups. Immune system process and binding are the important biological process and molecular function, respectively, in response to PM~10~ in COPD.\
**Abbreviation:** COPD, chronic obstructive pulmonary disease.](copd-10-831Fig1){#f1-copd-10-831}

![Serum PRG4, ITIH4, and APOF levels in healthy controls, smokers, and subjects with COPD.\
**Notes:** The PRG4 levels in subjects with COPD were significantly higher than in healthy controls and smokers, whereas the ITIH4 level in COPD was lower than in healthy controls (\**P*\<0.05).\
**Abbreviations:** APOF, apolipoprotein F; COPD, chronic obstructive pulmonary disease; ITIH4, inter-alpha-trypsin inhibitor heavy chain 4; PRG4, proteoglycan 4.](copd-10-831Fig2){#f2-copd-10-831}

![The relationship of serum PRG4, ITIH4, and APOF levels to 1-year, 2-year, and 3-year changes in PM~10~ levels.\
**Notes:** Study subjects were divided equally based on quintiles of PM~10~. The values in parentheses along the X-axis represent the mean PM~10~ values for each quintile group. Spearman's rank correlation coefficient was used to examine the correlation of quintiles of PM~10~ with PRG4, ITIH4, and APOF. PRG4 levels were correlated with the 2-year (*r*=0.278, *P*=0.033) and 3-year PM~10~ averages (*r*=0.349, *P*=0.007), whereas the ITIH4 levels were correlated with the 1-year (*r*=−0.325, *P*=0.012), 2-year (*r*=−0.401, *P*=0.002), and 3-year (*r*=−0.342, *P*=0.008) PM~10~ averages.\
**Abbreviations:** APOF, apolipoprotein F; ITIH4, inter-alpha-trypsin inhibitor heavy chain 4; PM~10~, particulate matter ≤10 μm; PRG4, proteoglycan 4.](copd-10-831Fig3){#f3-copd-10-831}

![Diagnostic performance of serum 8-isoprostane, CRP, PRG4, ITIH4, and APOF in receiver operating characteristic (ROC) curve analyses.\
**Notes:** ROC curve of the sensitivity and specificity of PRG4, ITIH4, and APOF levels for discriminating between the ≥50 μg/m^3^ and \<50 μg/m^3^ average 3-year PM~10~ value in COPD. The area under the curve value was 0.563 (95% CI: 0.413--0.713, *P*=0.405) for 8-isoprostane, 0.634 (95% CI: 0.486--0.782, *P*=0.086) for CRP, 0.636 (95% CI: 0.492--0.780, *P*=0.083) for PRG4, 0.690 (95% CI: 0.545--0.836, *P*=0.015) for ITIH4, and 0.523 (95% CI: 0.376--0.671, *P*=0.766) for APOF.\
**Abbreviations:** APOF, apolipoprotein F; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; ITIH4, inter-alpha-trypsin inhibitor heavy chain 4; PM~10~, particulate matter ≤10 μm; PRG4, proteoglycan 4.](copd-10-831Fig4){#f4-copd-10-831}

![Correlation of 8-isoprostane and CRP to PRG4, ITIH4, and APOF in subjects with COPD.\
**Notes:** The Spearman's rank correlation coefficient for CRP and ITIH4 was *r*=0.353 (*P*=0.005).\
**Abbreviations:** APOF, apolipoprotein F; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; ITIH4, inter-alpha-trypsin inhibitor heavy chain 4; PM~10~, particulate matter ≤10 μm; PRG4, proteoglycan 4.](copd-10-831Fig5){#f5-copd-10-831}

###### 

Baseline characteristics of healthy control subjects, smokers, and patients with COPD

  Categorical variables   Healthy controls (n=10)   Healthy smokers (n=5)   Patients with COPD (n=50)
  ----------------------- ------------------------- ----------------------- ---------------------------
  Age, years              67.8±6.2                  59.8±14.6               70.7±8.4
  Men, %                  75.0                      75.0                    95.5
  BMI, kg/m^2^            22.5±2.9                  24.8±4.0                23.8±3.7
  Current smoking, %      0                         100                     9.1
  FEV~1~, % predicted     88.0±11.5                 85.5±14.9               42.6±12.4
  8-Isoprostane, pg/mL    ND                        ND                      13.4±3.0
  CRP, mg/L               ND                        ND                      5.6±6.4

**Note:** Data is presented as mean ± SD.

**Abbreviations:** BMI, body mass index; FEV~1~, forced expiratory volume in 1 second; CRP, C-reactive protein; ND, no data.

###### 

Environmental exposure to PM~10~ over the previous 1 year, 2 years, and 3 years in the study subjects with COPD

                   PM~10~, μg/m^3^ (Mean ± SD)
  ---------------- -----------------------------
  1-year average   46.0±8.4
  2-year average   48.5±7.2
  3-year average   50.8±7.0

**Abbreviations:** PM~10~, particulate matter ≤10 μm; SD, standard deviation.
